Discontinuation of disease-modifying anti-rheumatic drugs and clinical outcomes in the Rheumatoid Arthritis DMARD Intervention and Utilisation Study 2 (RADIUS 2).
Saved in:
| Title: | Discontinuation of disease-modifying anti-rheumatic drugs and clinical outcomes in the Rheumatoid Arthritis DMARD Intervention and Utilisation Study 2 (RADIUS 2). |
|---|---|
| Authors: | Gibofsky A; Hospital for Special Surgery, New York, NY, USA., Cannon GW; Veterans Affairs Salt Lake City Health Care System and University of Utah School of Medicine, Salt Lake City, UT, USA., Harrison DJ; Amgen Inc., Thousand Oaks, CA, USA., Joseph GJ; Amgen Inc., Thousand Oaks, CA, USA., Bitman B; Amgen Inc., Thousand Oaks, CA, USA., Chaudhari S; KForce Clinical Research, Tampa, FL, USA., Collier DH; Amgen Inc., Thousand Oaks, CA, USA. |
| Source: | Clinical and experimental rheumatology [Clin Exp Rheumatol] 2015 May-Jun; Vol. 33 (3), pp. 297-301. Date of Electronic Publication: 2015 Feb 18. |
| Publication Type: | Journal Article; Multicenter Study; Observational Study; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Clinical And Experimental Rheumatology S.A.S Country of Publication: Italy NLM ID: 8308521 Publication Model: Print-Electronic Cited Medium: Print ISSN: 0392-856X (Print) Linking ISSN: 0392856X NLM ISO Abbreviation: Clin Exp Rheumatol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
